Actuate Therapeutics, Inc. Common stock Cash Flow-to-Debt Ratio
Actuate Therapeutics, Inc. Common stock cash flow-to-debt ratio. Actuate Therapeutics, Inc. Common stock (ACTU) has a Cash Flow-to-Debt Ratio of -0.99x as of September 2025, meaning its operating cash flow of $-6.68 Million could theoretically repay -1% of its total liabilities ($6.78 Million) in one year. See ACTU financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Actuate Therapeutics, Inc. Common stock (2022–2024)
Cash flow-to-debt ratio of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. Historical debt coverage capacity for Actuate Therapeutics, Inc. Common stock across 3 annual periods. Also explore Actuate Therapeutics, Inc. Common stock (ACTU) net asset momentum to track the company's year-over-year net asset growth rate.
Actuate Therapeutics, Inc. Common stock Cash Flow-to-Debt Ratio by Year (2022–2024)
Actuate Therapeutics, Inc. Common stock cash flow-to-debt ratio by year from 2022 to 2024. Year-by-year debt coverage analysis for Actuate Therapeutics, Inc. Common stock. For the full cash flow conversion analysis, see ACTU operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.37x | $-21.84 Million | $9.21 Million | ▼ -1024.9% |
| 2023 | -0.21x | $-21.63 Million | $102.62 Million | ▲ +93.3% |
| 2022 | -3.15x | $-17.79 Million | $5.65 Million | — |